Literature DB >> 23269785

A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice.

Melissa A Cobleigh1, Xin Wei, Michael D Robek.   

Abstract

Recombinant vesicular stomatitis virus (VSV) is a promising therapeutic vaccine platform. Using a transgenic mouse model of chronic hepatitis B virus (HBV) infection, we evaluated the therapeutic potential of a VSV vector expressing the HBV middle surface envelope glycoprotein (MS). VSV-MS immunization generated HBV-specific CD8 T cell and antibody responses in transgenic mice that express low HBV antigen levels. These findings support the further development of VSV as a therapeutic vaccine vector for chronic HBV.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23269785      PMCID： PMC3571382          DOI： 10.1128/JVI.02111-12

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  23 in total

1.  A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.

Authors:  Melissa A Cobleigh; Linda Buonocore; Susan L Uprichard; John K Rose; Michael D Robek
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.

Authors:  Yuan Hong; Yibing Peng; Michael Mi; Haiyan Xiao; David H Munn; Gui-Qiang Wang; Yukai He
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

3.  Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.

Authors:  Pierre Vandepapelière; George K K Lau; Geert Leroux-Roels; Yves Horsmans; Edward Gane; Tawesak Tawandee; Mohd Ismail bin Merican; Khin Maung Win; Christian Trepo; Graham Cooksley; Martine Wettendorff; Carlo Ferrari
Journal:  Vaccine       Date:  2007-10-24       Impact factor: 3.641

4.  The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.

Authors:  Melissa A Cobleigh; Clinton Bradfield; Yuanjie Liu; Anand Mehta; Michael D Robek
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

5.  Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection.

Authors:  Stephan Menne; Carol A Roneker; Brent E Korba; John L Gerin; Bud C Tennant; Paul J Cote
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice.

Authors:  A D Sette; C Oseroff; J Sidney; J Alexander; R W Chesnut; K Kakimi; L G Guidotti; F V Chisari
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

Review 7.  Is chronic hepatitis B being undertreated in the United States?

Authors:  C Cohen; S D Holmberg; B J McMahon; J M Block; C L Brosgart; R G Gish; W T London; T M Block
Journal:  J Viral Hepat       Date:  2010-12-08       Impact factor: 3.728

8.  Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.

Authors:  Pham Thi Le Hoa; Nguyen Tien Huy; Le The Thu; Cao Ngoc Nga; Kazuhiko Nakao; Katsumi Eguchi; Nguyen Huu Chi; Bui Huu Hoang; Kenji Hirayama
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

9.  Benefits and risks of interferon therapy for hepatitis B.

Authors:  Robert Perrillo
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

10.  Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein.

Authors:  John B Liao; Jean Publicover; John K Rose; Daniel DiMaio
Journal:  Clin Vaccine Immunol       Date:  2008-03-12
View more
  15 in total

1.  A Vesicular Stomatitis Virus-Based Vaccine Carrying Zika Virus Capsid Protein Protects Mice from Viral Infection.

Authors:  Xiaodan Shi; Jingping Hu; Jing Guo; Chuanjian Wu; Sidong Xiong; Chunsheng Dong
Journal:  Virol Sin       Date:  2019-02-28       Impact factor: 4.327

2.  Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8+ T cell responses in naïve and persistently infected mice and protects from challenge.

Authors:  Carolina Chiale; Safiehkhatoon Moshkani; John K Rose; Michael D Robek
Journal:  Antiviral Res       Date:  2019-05-30       Impact factor: 5.970

3.  Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins.

Authors:  Blair L DeBuysscher; Dana Scott; Andrea Marzi; Joseph Prescott; Heinz Feldmann
Journal:  Vaccine       Date:  2014-03-12       Impact factor: 3.641

Review 4.  Rhabdoviruses as vectors for vaccines and therapeutics.

Authors:  Gabrielle Scher; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2020-10-29       Impact factor: 7.090

5.  Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency.

Authors:  Mohamed A Farrag; Haitham M Amer; Peter Öhlschläger; Maaweya E Hamad; Fahad N Almajhdi
Journal:  Hum Vaccin Immunother       Date:  2017-03-08       Impact factor: 3.452

6.  Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model.

Authors:  Danqing Hu; Hongwu Wang; Hai Wang; Yaqi Wang; Xiaoyang Wan; Weiming Yan; Xiaoping Luo; Qin Ning
Journal:  Hepatol Int       Date:  2018-07-05       Impact factor: 6.047

7.  A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.

Authors:  Safiehkhatoon Moshkani; Carolina Chiale; Sabine M Lang; John K Rose; Michael D Robek
Journal:  J Virol       Date:  2019-02-19       Impact factor: 5.103

8.  Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.

Authors:  Ming Zhang; Chunsheng Dong; Sidong Xiong
Journal:  Hum Vaccin Immunother       Date:  2016-12-14       Impact factor: 3.452

9.  Long-distance interferon signaling within the brain blocks virus spread.

Authors:  Anthony N van den Pol; Siyuan Ding; Michael D Robek
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

10.  A fusion DNA vaccine encoding middle version of HBV envelope protein fused to interleukin-21 did not enhance HBV-specific immune response in mice.

Authors:  Ye Zhang; Wen-Jing Su; Jue Wang; Xue-Fan Bai; Chang-Xing Huang; Jian-Qi Lian
Journal:  Viral Immunol       Date:  2014-09-11       Impact factor: 2.257
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.